179 related articles for article (PubMed ID: 25611586)
41. Hepatitis B surface antigen seroclearance during chronic HBV infection.
Chu CM; Liaw YF
Antivir Ther; 2010; 15(2):133-43. PubMed ID: 20386068
[TBL] [Abstract][Full Text] [Related]
42. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
[TBL] [Abstract][Full Text] [Related]
44. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
[TBL] [Abstract][Full Text] [Related]
45. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
[TBL] [Abstract][Full Text] [Related]
46. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.
Liaw YF
Liver Int; 2009 Jan; 29 Suppl 1():100-7. PubMed ID: 19207972
[TBL] [Abstract][Full Text] [Related]
47. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine.
Wang XY; Zhang XX; Yao X; Jiang JH; Xie YH; Yuan ZH; Wen YM
Vaccine; 2010 Nov; 28(51):8169-74. PubMed ID: 20937312
[TBL] [Abstract][Full Text] [Related]
48. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Am J Med; 2006 Jan; 119(1):71.e9-16. PubMed ID: 16431195
[TBL] [Abstract][Full Text] [Related]
49. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection.
Ren F; Hino K; Yamaguchi Y; Funatsuki K; Hayashi A; Ishiko H; Furutani M; Yamasaki T; Korenaga K; Yamashita S; Konishi T; Okita K
J Med Virol; 2003 Nov; 71(3):376-84. PubMed ID: 12966542
[TBL] [Abstract][Full Text] [Related]
50. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck.
Kosinska AD; Liu J; Lu M; Roggendorf M
Med Microbiol Immunol; 2015 Feb; 204(1):103-14. PubMed ID: 25535101
[TBL] [Abstract][Full Text] [Related]
52. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection.
Chen YC; Jeng WJ; Chien RN; Chu CM; Liaw YF
Aliment Pharmacol Ther; 2016 Jun; 43(12):1311-8. PubMed ID: 27072504
[TBL] [Abstract][Full Text] [Related]
53. Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.
Chi H; Wong D; Peng J; Cao J; Van Hees S; Vanwolleghem T; Qi X; Chen L; Feld JJ; de Knegt RJ; Hansen BE; Janssen HLA
Clin Infect Dis; 2017 Aug; 65(4):680-683. PubMed ID: 28575292
[TBL] [Abstract][Full Text] [Related]
54. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.
Peng J; Cao J; Yu T; Cai S; Li Z; Zhang X; Sun J
Saudi J Gastroenterol; 2015; 21(4):245-53. PubMed ID: 26228369
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B.
Pol S; Nalpas B; Driss F; Michel ML; Tiollais P; Denis J; Brécho C;
J Hepatol; 2001 Jun; 34(6):917-21. PubMed ID: 11451177
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers.
Zhang Y; Bourgine M; Wan Y; Song J; Li Z; Yu Y; Jiang W; Zhou M; Guo C; Santucci D; Liang X; Brechot C; Zhang W; Charneau P; Wu H; Qiu C
J Hepatol; 2024 Jan; 80(1):31-40. PubMed ID: 37827470
[TBL] [Abstract][Full Text] [Related]
57. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.
Godon O; Fontaine H; Kahi S; Meritet JF; Scott-Algara D; Pol S; Michel ML; Bourgine M;
Mol Ther; 2014 Mar; 22(3):675-684. PubMed ID: 24394187
[TBL] [Abstract][Full Text] [Related]
58. Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile.
Shiue SJ; Cheng CL; Shiue HS; Chen CN; Cheng SW; Wu LW; Jargalsaikhan G; Chan TS; Lin HY; Wu MS
Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889747
[TBL] [Abstract][Full Text] [Related]
59. Long-Term Hepatitis B Surface Antigen Profile and Seroclearance Following Antiviral Treatment: A Single-Center, Real-World Cohort Study.
Huang CW; Yang CT; Su PY; Chen YY; Huang SP; Yen HH
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38001966
[TBL] [Abstract][Full Text] [Related]
60. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients.
Yip TC; Wong GL; Wong VW; Tse YK; Lui GC; Lam KL; Chan HL
J Hepatol; 2017 Oct; ():. PubMed ID: 28989093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
